For example, cathepsin activity is altered in leukocytes and cultured skin fibroblasts from CLN2 disease (Box 1) patients (Bennett et al., 1992), as well as in CLN3-depleted HeLa cells (Metcalf et al., 2008). The gene discussed is TPP1; the disease is glycogen storage disease VI.